Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 4/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 4/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8793068 | 0.98 | CYP1A2 (0.46) | CYP1A2SMN1; SMN2GSK3BCYP11B1CYP11B2 | |
| SCHEMBL626994 | 0.85 | GSK3B (0.49) | CYP1A2SMN1; SMN2GSK3BCYP11B1CYP11B2 | |
| SCHEMBL31503081 | 0.81 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2GSK3BOTUD7BCDK5 | |
| SCHEMBL29561358 | 0.81 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2GSK3BCYP11B1CYP11B2 | |
| SCHEMBL7102226 | 0.74 | — | — | |
| SCHEMBL7476995 | 0.74 | SMN1; SMN2 (0.55) | CYP1A2SMN1; SMN2GSK3BOTUD7BMAPT | |
| SCHEMBL1253734 | 0.73 | CA12 (0.38) | CYP1A2SMN1; SMN2GSK3BMEN1KMT2A | |
| SCHEMBL37900 | 0.73 | AHR (0.50) | CYP11B1CYP11B2MAPTMEN1KMT2A | |
| SCHEMBL29483964 | 0.73 | AHR (0.50) | CYP11B1CYP11B2MAPTMEN1KMT2A | |
| SCHEMBL29388854 | 0.73 | MAPT (0.33) | GSK3BCYP11B1CYP11B2CDK5GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | claimed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | claimed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | claimed |
| CN-108602823-B | Spiro-condensed pyrrolidine derivatives as Deubiquitinase (DUB) inhibitors | 特殊治疗有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | claimed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | claimed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | claimed |
| EP-3337476-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2018-06-27 | — | — | EP | claimed |
| EP-3157919-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2017-04-26 | — | — | EP | claimed |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2017-03-09 | — | — | US | claimed |
| WO-2017030814-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | Arvinas, Inc. (US) | 2017-02-23 | — | — | WO | claimed |
| EP-3019493-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | claimed |
| WO-2015193219-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| WO-2015193217-A1 | BET-PROTEIN INHIBITING DIHYDROPYRIDO[2,3-B]PYRAZINONE DERIVATIVES WITH PARA-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | claimed |
| EP-2935260-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | Bayer Pharma Aktiengesellschaft (DE) | 2015-10-28 | — | — | EP | claimed |
| WO-2015004075-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | claimed |
| WO-2014095774-A1 | BET-PROTEIN-INHIBITING DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-06-26 | — | — | WO | claimed |
| JP-6211855-A | — | — | None | — | — | JP | disclosed |
| JP-H06211855-A | AZAQUINOXALINES, THEIR PRODUCTION AND THEIR USE | HOECHST AG | 1994-08-02 | — | — | JP | disclosed |
| EP-0590428-A1 | Azaquinoxalines, process for their preparation, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CYP1A2 1843/4885SMN1; SMN2 4451/4885GSK3B 1821/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | CYP1A2 1843/4885SMN1; SMN2 4451/4885GSK3B 1821/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | CYP1A2 1843/4885SMN1; SMN2 4451/4885GSK3B 1821/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CYP1A2 4774/4885SMN1; SMN2 4324/4885GSK3B 1942/4885 |
| US-20170065719-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | CYP1A2 4774/4885SMN1; SMN2 4324/4885GSK3B 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.